Genetic Signatures Ltd (ASX: GSS) Share Price and News
Price
–
Movement
– ( )
(20 mins delayed)
52 Week Range
– - –
1 Year Return
Genetic Signatures Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$113.57 million
P/E Ratio
38.91
Dividend Yield
0.00%
Shares Outstanding
227.14 million
Earnings per share
-0.104
Dividend per share
N/A
Year To Date Return
-20.63%
Earnings Yield
2.57%
Franking
-
Share Price
–
Day Change
– ( )
52 Week Range
– - –
Yesterday's Close
–
Today's Open
–
Days Range
– - –
Volume
–
Avg. Volume (1 month)
–
Turnover
–
Genetic Signatures Ltd (ASX: GSS)
Latest News
Share Gainers
Why Afterpay, Genetic Signatures, Qube, & Serko shares are charging higher
❮2
GSS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|
About Genetic Signatures Ltd
Genetic Signatures Limited is a molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3Base™
GSS Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 31 Mar 2025 | $0.50 | $0.00 | 0.00% | 1,008,483 | $0.50 | $0.50 | $0.50 |
| 28 Mar 2025 | $0.50 | $0.00 | 0.00% | 5,492 | $0.51 | $0.51 | $0.50 |
| 27 Mar 2025 | $0.50 | $-0.07 | -12.39% | 14,983 | $0.52 | $0.52 | $0.49 |
| 26 Mar 2025 | $0.57 | $0.04 | 7.62% | 16,119 | $0.53 | $0.57 | $0.52 |
| 25 Mar 2025 | $0.53 | $0.02 | 3.92% | 42,624 | $0.52 | $0.53 | $0.52 |
| 21 Mar 2025 | $0.51 | $-0.01 | -1.92% | 16,160 | $0.51 | $0.51 | $0.51 |
| 20 Mar 2025 | $0.52 | $-0.02 | -3.70% | 29,173 | $0.55 | $0.55 | $0.52 |
| 19 Mar 2025 | $0.54 | $0.02 | 3.85% | 275,746 | $0.54 | $0.54 | $0.54 |
| 18 Mar 2025 | $0.52 | $-0.04 | -7.21% | 90,351 | $0.54 | $0.54 | $0.52 |
| 14 Mar 2025 | $0.56 | $0.02 | 3.70% | 3,221 | $0.56 | $0.56 | $0.56 |
| 13 Mar 2025 | $0.54 | $0.01 | 1.87% | 82,476 | $0.53 | $0.56 | $0.53 |
| 12 Mar 2025 | $0.54 | $0.02 | 3.88% | 93 | $0.54 | $0.54 | $0.54 |
| 11 Mar 2025 | $0.52 | $0.01 | 1.96% | 47,120 | $0.51 | $0.52 | $0.48 |
| 10 Mar 2025 | $0.51 | $-0.01 | -1.92% | 8,417 | $0.52 | $0.52 | $0.51 |
| 07 Mar 2025 | $0.52 | $-0.01 | -1.89% | 5,768 | $0.52 | $0.53 | $0.52 |
| 06 Mar 2025 | $0.53 | $0.00 | 0.00% | 221,698 | $0.52 | $0.54 | $0.52 |
| 05 Mar 2025 | $0.53 | $-0.03 | -5.41% | 202,718 | $0.55 | $0.55 | $0.53 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 16 Dec 2024 | Michael Aicher | Issued | 66,666 | $49,999 |
Issue of securities.
|
| 06 Dec 2024 | Neil Gunn | Issued | 500,000 | $317,500 |
Issue of options.
|
| 08 Jul 2024 | Anthony (Tony) Radford | Issued | 47,439 | $35,579 |
Rights issue.
|
| 08 Jul 2024 | Caroline Waldron | Issued | 3,302 | $2,476 |
Rights issue.
|
| 08 Jul 2024 | Stephane Chatonsky | Issued | 27,750 | $20,812 |
Rights issue.
|
| 02 Jul 2024 | Nicholas Samaras | Buy | 46,892 | $35,169 |
Off-market trade.
|
| 02 Jul 2024 | Nicholas Samaras | Sell | 46,892 | $35,169 |
Off-market trade.
|
| 13 Jun 2024 | Nicholas Samaras | Issued | 171,618 | $128,713 |
As advised by the company. Participation in the GSS Institutional Entitlement Offer.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Caroline Waldron | Non-Executive DirectorNon-Executive Chairman | May 2022 |
Ms Waldron is a cross-border advisor and director with over 30 years expertise in governance, marketing, human resources, and digital transformation across a range of sectors. Her formal training is in law, and she has been admitted to the Bar of England and Wales and the courts of other jurisdictions including Australia and New Zealand. She is a member of the Risk Committee.
|
| Dr Jenny Lee Harry | Non-Executive Director | Oct 2024 |
Dr Harry has over 25 years experience in executive management of companies in the biotechnology, diagnostic and pharmaceutical sectors. She is a CEO with experience in growing companies from start-up to commercialisation. Dr Harry is currently a Non-Executive Director of Neuren Pharmaceuticals Limited (ASX: NEU) and Aeris Environmental Ltd (ASX: AEI) and is a member of the IP Committee of the Childrens Medical Research Institute.
|
| Mr Michael Anton Aicher | Executive Director - US Operations | May 2014 |
Mr Aicher has over 30 years of industry experience and was CEO and founder of National Genetics Institute NGI which was acquired by Laboratory Corporation of America,Inc.LabCorp in 2000.Mr Aicher led LabCorp's Esoteric Business Units, which generated more than $1 billion in annual revenue. Prior to NGI, Mr. Aicher served in several executive leadership roles at Central Diagnostics Laboratory. He currently serves as a director on boards of Roswell Biotechnologies,Techcyte and CytoBay.
|
| Dr Neil Gunn | Non-Executive Director | Sep 2024 |
Mr Gunn has over 30 years of experience in medical devices and diagnostics. Most recently Dr Gunn was CEO of IDbyDNA, a metagenomics company based in the US that was acquired by Illumina in 2022. Prior to this he was the President of Roche Sequencing Solutions where he oversaw all aspects of the business and managed a team of approximately 900 people. His team developed and launched more than 20 products per year. Dr Gunn was also previously Vice President of Roche's Molecular Diagnostics business and was responsible for over 120 diagnostic product launches principally into the IVD clinical market.
|
| Ms Anne Nicole Lockwood | Non-Executive Director | Oct 2024 |
Ms Lockwood, is currently a Non-Executive Director for the ASX-listed company Mayne Pharma and Chief Financial Officer for Planet Innovation. She brings finance and accounting as well as US operations experience gained from senior executive roles in healthcare and life science companies.
|
| Mr Karl David Pechmann | Chief Financial OfficerChief Operating OfficerCompany Secretary | Jun 2023 |
-
|
| Mr Michael Sapountzis | Company Secretary | Feb 2025 |
-
|
| Ms Allison Rossiter | -- | Sep 2024 |
-
|
| Allison Rossiter | -- |
-
|
|
| Karl David Pechmann | Chief Financial OfficerChief Operating OfficerCompany Secretary |
-
|
|
| Michael Sapountzis | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Asia Union Investments Pty Ltd | 43,139,098 | 19.04% |
| Hsbc Custody Nominees (Australia) Limited | 39,532,373 | 17.45% |
| UBS Nominees Pty Ltd | 17,710,726 | 7.82% |
| BNP Paribas Noms Pty Ltd | 13,938,023 | 6.15% |
| Citicorp Nominees Pty Limited | 11,708,300 | 5.17% |
| J P Morgan Nominees Australia Pty Limited | 6,099,645 | 2.69% |
| Mirrabooka Investments Limited | 4,313,513 | 1.90% |
| Capital Concerns Pty Limited <Logue Family Super Fund A/C> | 4,032,191 | 1.78% |
| Bnp Paribas Nominees Pty Ltd <Clearstream> | 2,689,480 | 1.19% |
| Braham Consolidated Pty Ltd | 2,636,753 | 1.16% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 1,971,242 | 0.87% |
| Asia Union Investments Pty Ltd i | 1,809,937 | 0.80% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 1,671,273 | 0.74% |
| Idollink Pty Ltd <Mckeith Super Fund A/C> | 1,596,596 | 0.70% |
| Riddler Family Investments Pty Ltd | 1,406,013 | 0.62% |
| HSBC Custody Nominees (Australia) Limited i | 1,291,701 | 0.57% |
| Mr Michael Andrew Whiting & Mrs Tracey Anne Whiting <Whiting Family S/F A/C> | 1,237,854 | 0.55% |
| Quickinvest Pty Ltd <Quickinvest Staff S/F A/C> | 1,173,384 | 0.52% |
| Juleyu Pty Ltd <Phillip Isaacs S/F A/C> i | 993,020 | 0.43% |
| Mr Alistair David Strong | 900,000 | 0.40% |